Pulse Biosciences (NASDAQ:PLSE) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Pulse Biosciences (NASDAQ:PLSE) announced its earnings results on Thursday. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.01), Zacks reports. Pulse Biosciences had a negative return on equity of 94.42% and a negative net margin of 6,755.78%. The company had revenue of $0.40 million for the quarter, compared to analyst estimates of $0.52 million. During the same period in the previous year, the firm posted ($0.29) earnings per share. The firm’s quarterly revenue was down 54.1% compared to the same quarter last year.

Here are the key takeaways from Pulse Biosciences’ conference call:

• Pulse completed enrollment in its NANOPULSE-AF pivotal study with 169 evaluable patients, three months ahead of its original schedule. Patients are now in follow-up, with blended six- and 12-month results expected in Q3 2027.
• Preliminary PRECISE-BTN results showed that a single Vybrance treatment reduced thyroid nodule volume by more than 50% in 86% of patients, with a 78% average improvement in quality-of-life scores at six months and no serious adverse events reported. Further follow-up is due in 2027 and will support a planned 510(k) submission.
• The company ended the quarter with $189.2 million in cash and marketable securities, which management says provides roughly two years of runway; about $64 million of ATM capacity remains. It plans to use capital for clinical programs and manufacturing and commercial-launch preparation.
• Q3 revenue was just $395,000, while GAAP net loss widened to $23.1 million from $19.4 million a year earlier. Management expects quarterly non-GAAP costs and expenses to rise 15%–25% above the roughly $20 million average in Q2 and Q3 as clinical and pre-commercial investment increases.
• Pulse is preparing manufacturing capacity and market-launch plans for its nPulse catheter, targeting launch readiness beginning in early 2028 and remaining open to a partnership or other launch structure. However, strategic discussions have not produced a disclosed deal, and management said partners are waiting for further clinical and regulatory evidence.

Pulse Biosciences Stock Performance

NASDAQ PLSE traded up $0.22 during mid-day trading on Friday, hitting $53.29. The stock had a trading volume of 428,197 shares, compared to its average volume of 373,557. Pulse Biosciences has a 52-week low of $12.56 and a 52-week high of $58.90. The company has a 50 day simple moving average of $51.55 and a 200 day simple moving average of $32.28.

Insider Buying and Selling

In other news, COO Liane Teplitsky acquired 1,036 shares of the business’s stock in a transaction on Wednesday, August 26th. The shares were purchased at an average price of $48.23 per share, for a total transaction of $49,966.28. Following the acquisition, the chief operating officer directly owned 1,036 shares of the company’s stock, valued at $49,966.28. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have purchased a total of 4,095 shares of company stock valued at $199,931 in the last 90 days. Company insiders own 74.00% of the company’s stock.

More Pulse Biosciences News

Here are the key news stories impacting Pulse Biosciences this week:

• Positive Sentiment: Six-month interim results from the PRECISE-BTN study of Pulse’s nano-pulsed field ablation treatment for thyroid nodules were described as positive. The update adds clinical evidence for the technology. Article: Pulse Biosciences’ NsPFA Treatment Shows Positive Six-Month Thyroid Study Results Article: Six-Month PRECISE-BTN Study Results
• Positive Sentiment: Canaccord Genuity raised its price target from $58 to $74 and maintained a Buy rating; Needham also reiterated Buy and raised its target from $58 to $64. These higher targets reflect improved analyst expectations. Canaccord Genuity recommendations Needham recommendations
• Positive Sentiment: The company said it completed enrollment in its U.S. pivotal IDE study in six months, three months ahead of schedule—progress toward advancing its technology. Business updates and Q3 results
• Negative Sentiment: Pulse plans a 15%–25% increase in quarterly non-GAAP expenses as it works toward a Q4 2027 CE Mark target. The added spending could weigh on cash use and future losses. Expense outlook and CE Mark target
• Negative Sentiment: Q3 revenue was $400,000, below the approximately $521,000 estimate and down 54.1% year over year. The $0.32 per-share loss was also slightly wider than the $0.31 consensus loss, underscoring the company’s limited current revenue base. Q3 results coverage

Wall Street Analyst Weigh In

Several analysts have issued reports on PLSE shares. Mizuho set a $65.00 target price on Pulse Biosciences in a research note on Friday. Canaccord Genuity Group boosted their price objective on shares of Pulse Biosciences from $58.00 to $74.00 and gave the stock a “buy” rating in a research note on Friday. Freedom Capital raised shares of Pulse Biosciences to a “strong-buy” rating in a report on Wednesday, September 9th. Needham & Company LLC increased their price target on Pulse Biosciences from $58.00 to $64.00 and gave the company a “buy” rating in a research note on Friday. Finally, BTIG Research initiated coverage on shares of Pulse Biosciences in a research note on Wednesday, September 23rd. They set a “buy” rating and a $70.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $66.60.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc (NASDAQ:PLSE) is a medical technology company developing bioelectric therapies based on its Nano-Pulse Stimulation (NPS) technology. The technology uses short, high-voltage electrical pulses to create temporary openings in cell membranes, with the goal of selectively affecting targeted cells while limiting thermal damage to surrounding tissue.

The company’s principal product is the CellFX System, a device designed to deliver NPS treatments for certain dermatologic conditions.